FDA Approves FENOFIBRIC ACID — Macleods Pharmaceuticals Limited

Macleods Pharmaceuticals Limited has received FDA Approval for its Abbreviated New Drug Application (ANDA207796) for generics of the Hypercholesteremia treatment FENOFIBRIC ACID, signaling the imminent expansion of affordable lipid-lowering options amid projected patent expirations in the space. The approval is expected to deepen the competitive landscape for cholesterol management by driving price pressure and increasing accessibility for managed care organizations.